about
Pre-emptive correction for haemodialysis arteriovenous access stenosisProgrammatic variation in home hemodialysis in Canada: results from a nationwide survey of practice patterns.Overview of the Alberta Kidney Disease Network.Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients.The VITAH trial VITamin D supplementation and cardiac Autonomic tone in Hemodialysis: a blinded, randomized controlled trialConservative management of an iatrogenic arteriovenous fistula.Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections.Serum uric acid level, blood pressure, and vascular angiotensin II responsiveness in healthy men and womenRole of vascular function in predicting arteriovenous fistula outcomes: an observational pilot study.Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial.Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms.A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients.Vascular access and cardiac disease: is there a relationship?Associations between hemodialysis access type and clinical outcomes: a systematic review.Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS).Arteriovenous Vascular Access Selection and Evaluation.Arteriovenous Access Failure, Stenosis, and Thrombosis.Practical Aspects of Nontunneled and Tunneled Hemodialysis Catheters.Hemodialysis Tunneled Catheter-Related InfectionsArteriovenous Access: Infection, Neuropathy, and Other Complications.Hemodialysis Tunneled Catheter Noninfectious Complications.Canadian Society of Nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis.The buttonhole technique for fistula cannulation: pros and cons.The care and keeping of vascular access for home hemodialysis patients.Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Impact of using two dialyzers in parallel on phosphate clearance in hemodialysis patients: a randomized trial.Emergency Department Use among Patients with CKD: A Population-Based Analysis.A Clinical Risk Prediction Tool for 6-Month Mortality After Dialysis Initiation Among Older Adults.Examining the Association between Hemodialysis Access Type and Mortality: The Role of Access Complications.The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death.Extracellular fluid management and hypertension in urban dwelling versus rural dwelling hemodialysis patients.The association between intradialytic exercise and hospital usage among hemodialysis patients.The VITAH Trial-Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled TrialUltrafiltration biofeedback guided by blood volume monitoring to reduce intradialytic hypotensive episodes in hemodialysis: study protocol for a randomized controlled trial.Vascular Access Core Curriculum: Introduction.25-Hydroxyvitamin D status, arterial stiffness and the renin-angiotensin system in healthy humans.Sex influences the effect of body mass index on the vascular response to angiotensin II in humans.Randomized Crossover Trial of Blood Volume Monitoring-Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis.Sex differences in associations between insulin resistance, heart rate variability, and arterial stiffness in healthy women and men: a physiology study.Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution.
P50
Q24186556-E2A56D3F-5682-4F8D-9EAC-C1ADAC15F89BQ30624481-9A097230-FF93-46C9-9185-652A86BCE3A7Q33511358-E3B58A3B-5298-438A-8B00-27BE9302A0C2Q34029236-77735332-96DE-4F92-8448-59502DE26F71Q34033076-2576D632-6BD2-4F22-994F-73B9B8CA1725Q34472011-5DD6D2CC-D6B1-410F-981A-493847388BEFQ34769989-3C1D237F-FEC1-411D-9C89-94B0CEDBBF9AQ35094181-DD07EA87-6E38-40B5-8458-B86C34E9BD09Q35577092-8C28CE13-89F2-474A-80C3-2EAA7A0FC5BCQ35583909-E4F84DF2-0E92-434E-8BA5-2F433425AE89Q35757838-326C6535-0C7C-49A2-9F8C-FEAF958C83D4Q36294347-288893D6-4C32-45FF-9C52-9DD03FA6818AQ36629438-1F860B4A-D77C-4D64-85F7-52AF2990FC9BQ36638364-FDFA8C0F-46CE-4E20-B451-F0AC01C87923Q36666731-F9AC1D6B-AEB9-4DFF-B5A8-64B9AB6DA613Q37674504-553308AC-FA54-4A7A-A866-644CBEE750ACQ37674518-A576F599-73A6-4FCA-97DF-6100389B21F0Q37674525-3EF24B72-1988-4B60-8FA6-257872596CB9Q37674533-8ADC53E2-544D-43F7-BE50-B7D7862A6BEBQ37674538-054B7144-E4E8-4518-B4E0-F802B8CE6917Q37674559-ED96BA8A-A38C-4AD4-9D47-1EBAC1F4C71DQ38097157-0F0368EE-C09D-43F6-9FD8-1CB94E8B57C0Q38146483-7721668F-09D8-40CC-895F-C39987E8C2FAQ38450140-FBFB0EE6-9223-4806-922F-14D5BF9A2CCCQ38699718-B920A782-E782-4906-A36C-B41CDEBDE327Q38865935-FFD8813E-19EE-4924-8F3A-ED6CBB0A7219Q39001156-60235997-4F29-4344-8319-052CD1D3A9FFQ39180217-1A0CDE88-1625-42BE-8CDA-96DF1C050977Q40206761-27BDDE6F-0C05-4015-96A8-3EFC4094854EQ40351254-32E32763-366F-43AC-8A07-4D6A23EE63CDQ40399701-AA924DE7-2F0C-4C12-9B0D-907478C7EC6AQ41144766-722CD556-79D3-46DE-8010-96EBFB3C6527Q41602515-82D80AC6-9369-4C92-94C3-9B342B92532BQ41849825-6B7A0EB2-01C7-44E4-8E3F-C3986B43A752Q42318997-700B8709-FF4A-4368-B520-30AD4DEAC64EQ44234758-8719A5CD-34EF-4296-83B5-F49DF26A6A14Q44634038-4D138B13-9978-40BC-8CD1-8924456D3280Q47849007-B9085206-4C12-4D26-BD88-8BBC9F7C9F05Q47886938-5BC9C415-2628-44A6-ADEF-8FA34EAB3108Q48240891-0640738E-96EE-4063-8C7E-D340E4AE3D48
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
Jennifer M MacRae
@en
Jennifer M MacRae
@nl
type
label
Jennifer M MacRae
@en
Jennifer M MacRae
@nl
prefLabel
Jennifer M MacRae
@en
Jennifer M MacRae
@nl
P106
P31
P496
0000-0002-4711-1440